Literature DB >> 14991762

Dynamic process of prostate cancer metastasis to bone.

Kwanchanit Tantivejkul1, Linda M Kalikin, Kenneth J Pienta.   

Abstract

Prostate cancer metastasis to the bone occurs at high frequency in patients with advanced disease, causing significant morbidity and mortality. Over a century ago, the "seed and soil" theory was proposed to explain organ-specific patterns of metastases. Today, this theory continues to be relevant as we continue to discover factors involved in the attraction and subsequent growth of prostate cancer cells to the bone. These include the accumulation of genetic changes within cancer cells, the preferential binding of cancer cells to bone marrow endothelial cells, and the release of cancer cell chemoattractants from bone elements. A key mediator throughout this metastatic process is the integrin family of proteins. Alterations in integrin expression and function promote dissociation of cancer cells from the primary tumor mass and migration into the blood stream. Once in circulation, integrins facilitate cancer cell survival through interactions between other cancer cells, platelets, and endothelial cells of the target bone. Furthermore, dynamic changes in integrins and in integrin-associated signal transduction aid in the extravasation of cancer cells into the bone and in expansion to a clinically relevant metastasis. Thus, we will review the critical roles of integrins in the process of prostate cancer bone metastasis, from the escape of cancer cells from the primary tumor, to their survival in the harsh "third microenvironment" of the circulation, and ultimately to their attachment and growth at distant bone sites. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991762     DOI: 10.1002/jcb.10664

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  35 in total

1.  Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

Authors:  Deborah A Bradley; Stephanie Daignault; Charles J Ryan; Robert S Dipaola; Kathleen A Cooney; David C Smith; Eric Small; Paul Mathew; Mitchell E Gross; Mark N Stein; Alice Chen; Kenneth J Pienta; June Escara-Wilke; Gerald Doyle; Mahmoud Al-Hawary; Evan T Keller; Maha Hussain
Journal:  Invest New Drugs       Date:  2010-03-25       Impact factor: 3.850

2.  Increased potency of the PHSCN dendrimer as an inhibitor of human prostate cancer cell invasion, extravasation, and lung colony formation.

Authors:  Hongren Yao; Donna M Veine; Zhao-Zhu Zeng; Kevin S Fay; Evan D Staszewski; Donna L Livant
Journal:  Clin Exp Metastasis       Date:  2010-03-26       Impact factor: 5.150

Review 3.  Targeted approaches for the management of metastatic prostate cancer.

Authors:  Kathleen W Beekman; Maha Hussain
Journal:  Curr Oncol Rep       Date:  2006-05       Impact factor: 5.075

Review 4.  Integrins in prostate cancer progression.

Authors:  Hira Lal Goel; Jing Li; Sophia Kogan; Lucia R Languino
Journal:  Endocr Relat Cancer       Date:  2008-06-04       Impact factor: 5.678

5.  Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules.

Authors:  Anand Ramteke; Harold Ting; Chapla Agarwal; Samiha Mateen; Ranganathan Somasagara; Anowar Hussain; Michael Graner; Barbara Frederick; Rajesh Agarwal; Gagan Deep
Journal:  Mol Carcinog       Date:  2013-12-17       Impact factor: 4.784

6.  Design, synthesis and validation of integrin α2β1-targeted probe for microPET imaging of prostate cancer.

Authors:  Chiun-Wei Huang; Zibo Li; Hancheng Cai; Kai Chen; Tony Shahinian; Peter S Conti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-25       Impact factor: 9.236

Review 7.  Significance of talin in cancer progression and metastasis.

Authors:  Andreas Desiniotis; Natasha Kyprianou
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

8.  Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.

Authors:  Geertje van der Horst; Christel van den Hoogen; Jeroen T Buijs; Henry Cheung; Henny Bloys; Rob C M Pelger; Giocondo Lorenzon; Bertrand Heckmann; Jean Feyen; Philippe Pujuguet; Roland Blanque; Philippe Clément-Lacroix; Gabri van der Pluijm
Journal:  Neoplasia       Date:  2011-06       Impact factor: 5.715

9.  Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells.

Authors:  Charles J Dimitroff; Leyla Descheny; Natalia Trujillo; Robert Kim; Vuong Nguyen; Wei Huang; Kenneth J Pienta; Jeffery L Kutok; Mark A Rubin
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

Review 10.  Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.